Nasdaq has filed to list the 21Shares SUI ETF with the U.S. SEC on June 11, 2025.
This filing is seen as a significant institutional step for the Sui blockchain ecosystem, suggesting increased financial engagement and market viability.
Nasdaq Files for 21Shares SUI ETF Listing with SEC
Nasdaq has submitted an SEC application to list the spot 21Shares SUI ETF, officially marking the beginning of the SEC’s review process, according to the SEC register. In April, 21Shares had already filed an S-1 registration, paving the way for further inclusion within the U.S. market.
The launch of the SUI ETF showcases growing institutional recognition of the Sui platform. By offering a vehicle for investors interested in SUI, the ETF could drive demand for the token, potentially influencing prices and on-chain activities, such as liquidity and staking measures.
“Nasdaq’s 19b-4 filing officially posts to SEC register, marking formal start of review process for the U.S. spot SUI ETF.” – Sui Foundation, Official Blog
Initial market reactions appear optimistic, with enhanced interest in the Sui ecosystem anticipated. At this time, however, there have been no public statements from Sui Foundation leadership or executives from 21Shares acknowledging the application event.
Spot ETFs to Potentially Impact SUI Market Dynamics
Did you know? The introduction of spot cryptocurrency ETFs like Bitcoin and Ethereum previously led to notable trading and price shifts, highlighting possible parallels for SUI.
CoinMarketCap data shows Sui’s current price at $3.48, with a market cap of $11.81 billion and a 24-hour trading volume at $1.00 billion. Recent trends show a 2.19% 24-hour price increase and a 5.80% rise over seven days. Price fluctuations indicate increased investor activity since the ETF discussions began.
The Coincu research team highlights potential implications, with the ETF likely bolstering Sui’s institutional adoption. It may further influence SUI’s market dynamics and price volatility, contributing to a strengthened blockchain position pending regulatory approval.
